Drug intelligence / Profile preview

SYH2066

Development stage: Unknown
Lead developer: CSPC Ouyi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

SYH2066 is an investigational oral small molecule antiviral candidate developed by CSPC Ouyi Pharmaceutical (a subsidiary of CSPC Pharmaceutical Group) for the treatment of respiratory syncytial virus (RSV) infection. The drug is designed to inhibit viral replication, addressing a significant unmet need in respiratory medicine, particularly for vulnerable populations such as infants and the elderly. As of early 2025, SYH2066 is in Phase 1 clinical development in China (CTR20253751), where it is being evaluated in a randomized, double-blind, placebo-controlled study to determine its safety, tolerability, and pharmacokinetic profile, as well as the effect of food on its bioavailability in healthy adult participants.

Beyond the preview

Go deeper on SYH2066.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYH2066.

Explore the full profile